Scarica l'app Stockscreener
5.20
0.38%
-0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRVI Giù?
Forum
Previsione
Precedente Chiudi:
$5.22
Aprire:
$5.31
Volume 24 ore:
8.41M
Relative Volume:
3.40
Capitalizzazione di mercato:
$767.03M
Reddito:
$204.73M
Utile/perdita netta:
$-184.29M
Rapporto P/E:
-7.1962
EPS:
-0.7226
Flusso di cassa netto:
$-51.87M
1 W Prestazione:
-0.19%
1M Prestazione:
+27.45%
6M Prestazione:
+47.73%
1 anno Prestazione:
+158.71%
Intervallo 1D:
$5.01
$5.31
Intervallo di 1 settimana:
$4.8514
$5.315
Portata 52W:
$1.99
$5.315
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Nome
Maravai Lifesciences Holdings Inc
Settore
Industria
Telefono
(858) 546-0004
Indirizzo
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
5.20 | 767.03M | 204.73M | -184.29M | -51.87M | -0.7226 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | Iniziato | Guggenheim | Neutral |
| 2024-12-05 | Downgrade | Goldman | Neutral → Sell |
| 2024-11-14 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-08 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | Iniziato | Craig Hallum | Buy |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-08-08 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | Downgrade | Goldman | Buy → Neutral |
| 2023-01-05 | Downgrade | UBS | Buy → Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-11-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2020-12-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | Iniziato | BofA Securities | Buy |
| 2020-12-15 | Iniziato | Credit Suisse | Outperform |
| 2020-12-15 | Iniziato | Goldman | Buy |
| 2020-12-15 | Iniziato | Jefferies | Buy |
| 2020-12-15 | Iniziato | Robert W. Baird | Outperform |
| 2020-12-15 | Iniziato | Stifel | Buy |
| 2020-12-15 | Iniziato | William Blair | Outperform |
| 2020-12-14 | Iniziato | UBS | Buy |
Mostra tutto
Maravai Lifesciences Holdings Inc Borsa (MRVI) Ultime notizie
Maravai LifeSciences Holdings Inc (MRVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Institutional Confidence - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Maravai LifeSciences Holdings Inc - TradingKey
Maravai LifeSciences Holdings Inc (MRVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maravai LifeSciences (MRVI) Launches New GMP Enzyme Manufacturin - GuruFocus
Maravai LifeSciences Stock (US56600D1072): TriLink opens new GMP enzyme facility in Florida - AD HOC NEWS
MRVI PE Ratio & Valuation, Is MRVI Overvalued - Intellectia AI
TriLink Opens GMP Enzyme Manufacturing Facility In Jupiter, Florida - marketscreener.com
TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale - Business Wire
Maravai LifeSciences refinances debt with $180M credit facilities; lowers outstanding borrowings - MSN
Maravai LifeSciences Holdings, Inc. (MRVI) tops Q1 earnings and revenue estimates - MSN
Insider Sell: Kurt Oreshack Sells 50,000 Shares of Maravai LifeS - GuruFocus
Maravai LifeSciences general counsel Oreshack sells $253,999 shares By Investing.com - Investing.com Nigeria
Maravai LifeSciences general counsel Oreshack sells $253,999 shares - Investing.com
Maravai Lifesciences Holdings Insider Sold Shares Worth $254,000, According to a Recent SEC Filing - Moomoo
MRVI (MRVI) CEO Brust reports 351,001-share tax withholding, holds 2.1M shares - Stock Titan
Maravai (NASDAQ: MRVI) General Counsel sells 50,000 shares under 10b5-1 plan - Stock Titan
Maravai Lifesciences director gifts 92,586 shares | MRVI Insider Trading - Stock Titan
Kurt Oreshack notifies sale of 25,000 MRVI Class A shares (NASDAQ: MRVI) - Stock Titan
MRVI SEC FilingsMaravai Lifesciences Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Maravai (MRVI) brokered sale notice: 25,000 Class A shares via Fidelity - Stock Titan
Maravai LifeSciences Projects Strong Annual Revenue and Trims Q1 Net Loss - HarianBasis.co
This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio - Yahoo Finance
MRVI Technical Analysis & Stock Price Forecast - Intellectia AI
MRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Investors’ Stock Portfolio: Top 10 Penny Stocks To Buy - Insider Monkey
Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025MRVI - ACCESS Newswire
Maravai LifeSciences refinances debt, cuts principal by $92.9M - Investing.com UK
Maravai LifeSciences (MRVI) Secures New $150M Credit Facility - GuruFocus
Maravai LifeSciences refinances debt, cuts principal by $92.9M By Investing.com - Investing.com Australia
Maravai LifeSciences Refinances Debt, Extends Credit Facilities - TipRanks
Maravai LifeSciences Refinances Credit Agreement, Extends Maturity to 2032 - Moomoo
Maravai LifeSciences (NASDAQ: MRVI) cuts debt and extends loan maturity to 2032 - Stock Titan
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032 - Business Wire
Maravai Stock Dips Monday With Eyes on Major Event This Week - Bez Kabli
Maravai LifeSciences Holdings, Inc. 8-K Filing Details for May 26, 2026: Company Information, Stock, and Regulatory Compliance - Minichart
Maravai Lifesciences Shareholders Back Board, Pay, Auditor - TipRanks
Maravai LifeSciences (MRVI) shareholders approve directors, auditor and pay at 2026 meeting - Stock Titan
All you need to know about Maravai LifeSciences (MRVI) rating upgrade to buy - MSN
Maravai (MRVI) director granted 46,293 restricted stock units - Stock Titan
Maravai LifeSciences (MRVI) Surges Over 6% as Biotech Sector Shows Signs of LifeRisk Parity Rebalance - thelegaladvocate.com
Director-linked entity at Maravai (NASDAQ: MRVI) awarded 46,293 RSUs - Stock Titan
Maravai (MRVI) director Susannah Gray receives 46,293-share stock unit award - Stock Titan
Maravai (MRVI) director Mihas receives 46,293 RSUs held for GTCR-affiliated entity - Stock Titan
Maravai LifeSciences (MRVI) director receives 46,293-share RSU award - Stock Titan
Maravai Lifesciences Holdings Inc Azioni (MRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):